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OBJECTIVE—Animal studies indicate a prominent role of brain
insulin signaling in the regulation of peripheral energy metabo-
lism. We determined the effect of intranasal insulin, which
directly targets the brain, on glucose metabolism and energy
expenditure in humans.
RESEARCH DESIGN AND METHODS—In a double-blind,
placebo-controlled, balanced within-subject comparison, 19
healthy normal-weight men (18–26 years old) were intranasally
administered 160 IU human insulin after an overnight fast.
Energy expenditure assessed via indirect calorimetry and blood
concentrations of glucose, insulin, C-peptide, and free fatty acids
(FFAs) were measured before and after insulin administration
and the subsequent consumption of a high-calorie liquid meal of
900 kcal.
RESULTS—Intranasal insulin, compared with placebo, in-
creased postprandial energy expenditure, i.e., diet-induced ther-
mogenesis, and decreased postprandial concentrations of
circulating insulin and C-peptide, whereas postprandial plasma
glucose concentrations did not differ from placebo values. Intra-
nasal insulin also induced a transient decrease in prandial serum
FFA levels.
CONCLUSIONS—Enhancing brain insulin signaling by means
of intranasal insulin administration enhances the acute thermo-
regulatory and glucoregulatory response to food intake, suggest-
ing that central nervous insulin contributes to the control of
whole-body energy homeostasis in humans. Diabetes 60:114–
118, 2011
A
nimal studies have yielded evidence that the
regulation of whole-body energy ﬂux critically
depends on intact brain insulin signaling (1,2).
Most recent ﬁndings have shown that the hypo-
thalamic administration of insulin increases brown adi-
pose tissue thermogenesis by direct inhibitory effects on
warm-sensitive neurons (3). Moreover, studies in rodents
have demonstrated that in addition to its direct inhibitory
effect on hepatic gluconeogenesis, insulin acts in the
hypothalamus to decrease glucose production in the liver
(4,5), thus establishing an insulin-driven brain-liver axis
that controls systemic glucose homeostasis. We examined
whether insulin acting in the human brain exerts compa-
rable effects on energy homeostasis by administering
intranasal insulin that bypasses the blood-brain barrier
and reaches the brain compartment along the olfactory
nerve (6,7), modulating central nervous functions in the
absence of relevant peripheral effects (8). Notably, intra-
nasal insulin reduces food intake (9) and body fat content
(10) in healthy men, indicating that following intranasal
administration, the hormone accesses neuronal networks
relevant for energy homeostasis. Against this background,
in the present study we assessed the effects of intranasal
insulin on the glucoregulatory and thermoregulatory re-
sponse to food intake in humans.
RESEARCH DESIGN AND METHODS
Nineteen healthy men (mean  SEM age 23.2  0.6 years and BMI 23.5  0.3
kg/m
2) who were free of medication participated in the experiments. They
gave written informed consent to the study, which conformed to the Decla-
ration of Helsinki and was approved by the local ethics committee.
Experimental protocol. Each subject participated in two conditions (insulin
and placebo) spaced apart by at least 4 weeks. The order of conditions was
balanced across subjects. Body weight and body composition (BIA 2000-M;
Data Input, Frankfurt, Germany) did not differ between conditions.
After a 12-h fast, experimental sessions started at 7:00 A.M. with baseline
assessments of energy expenditure and blood parameters (Fig. 1). Throughout
the experiment, subjects rested in bed in a supine position in a quiet room of
constant temperature (23°C). At 9:10 A.M., sixteen 0.1-ml puffs (eight per
nostril) of insulin and placebo, respectively, were intranasally administered in
2-min intervals, amounting to a total dose of 1.6 ml insulin (160 IU Insulin
Actrapid; Novo Nordisk, Mainz, Germany) or vehicle (HOE 31 dilution buffer;
Aventis Pharma, Bad Soden, Germany). Insulin and placebo were adminis-
tered using precision air pumps (Aero Pump, Hochheim, Germany) that ﬁll the
nostrils and the nasal cavity with aerosol, thus enabling the solution to
effectively target the olfactory epithelium. The dose of intranasal insulin used
here has previously been shown to be functionally effective in healthy humans
(9,11). Following postinsulin administration measurements (see below), sub-
jects consumed 600 ml of a standard liquid meal (Fresubin energy drink,
Fresenius Kabi, Bad Homburg, Germany) at a dose of 20 ml/min (totaling 900
kcal, 33.6 g protein, 34.8 g fat, and 112.8 g carbohydrate) from 10:15–10:45:00 A.M.,
and subsequently assessments were continued until 4:00 P.M.
Assessments. Energy expenditure (expressed as kcal/min) was measured via
indirect calorimetry using a ventilated-hood system (Deltatrac II, MBM-200
Metabolic Monitor; Datex-Engstro ¨m Deutschland, Achim, Germany). Before
each use, the device was calibrated with Quick Cale calibration gas to 5% CO2
and 95% O2. Calorimetric measurements took place from 8:30 to 9:00 A.M.
(baseline), from 9:45 to 10:15:00 A.M. (to assess effects of intranasal insulin
alone), and ﬁve times between 10:45 and 3:15:00 P.M., i.e., after liquid food
intake (Fig. 1). The rise in energy expenditure between the fasting state
(baseline measurement from 8:45 to 9:15:00 A.M.) and the postprandial state
(mean energy expenditure from 10:45 to 3:15:00 P.M.) reﬂects diet-induced
thermogenesis, i.e., the energy that is emitted as heat during food metaboliza-
tion and thus does not contribute to the production of ATP. Postprandial
measurements were separated by 30-min breaks during which the ventilation
hood was not worn but the subjects remained in bed.
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insulin, C-peptide, and free fatty acids (FFAs), blood was sampled twice during
baseline (8:00 and 9:00 A.M.), immediately after intranasal insulin administration
(9:40 A.M.), every 10 min during liquid food intake (10:20–10:40 A.M.), and at
60-min intervals thereafter (11:30 A.M.–2:30 P.M.) with a ﬁnal sample taken at
4:00 P.M. (Fig. 1). Plasma glucose levels were measured in ﬂuoride plasma
(hexokinase method, Aeroset; Abbott Diagnostics, North Chicago, IL). Serum
concentrations of insulin and C-peptide were measured by an Immulite
analyzer (Siemens Medical Solutions Diagnostics, Los Angeles, CA). FFA
concentrations were measured by enzymatic assays as previously described
(12).
Statistical analysis. Data are presented as means  SEM. Statistical
analyses were based on ANOVA including the repeated-measures factors
condition and time (referring to the immediate posttreatment and postpran-
dial periods). Postprandial glucose and hormone concentrations (10:20 A.M.–
4:00 P.M.) were expressed as areas under the curve (AUCs) calculated
according to the trapezoidal rule. Post hoc two-sided t tests were used for
single time point comparisons. A P value 0.05 was considered signiﬁcant.
RESULTS
Resting metabolic rates were comparable between condi-
tions during baseline and immediately after insulin admin-
istration (P  0.19 for all comparisons) (Fig. 2). However,
the increase in metabolic rate following liquid food intake
was on average 17% greater in the insulin than in the
placebo condition (P  0.05 for the insulin/placebo main
effect; Fig. 2), indicating an increase in postprandial en-
ergy expenditure, i.e., diet-induced thermogenesis, due to
intranasal insulin.
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FIG. 1. Experimental schedule. Nineteen healthy subjects who had fasted overnight spent the experimental day sitting in bed in a supine position.
Measurements of energy expenditure by 30-min periods of indirect calorimetry were performed during baseline (8:30–9:00 A.M.), immediately
after intranasal insulin administration (9:45–10:15:00 A.M., 1.6 ml [160 IU] insulin and placebo, respectively; nose symbol), and ﬁve times
following the standardized consumption of a predeﬁned liquid meal of 900 kcal (cup symbol). Blood samplings for the determination of plasma
glucose, serum insulin, C-peptide, and free fatty acids concentrations are indicated by syringe symbols.
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FIG. 2. Intranasal insulin enhances postprandial energy expenditure. Following baseline assessment of energy expenditure (EE) (expressed per
kcal/min), acute effects of intranasal administration (nose symbol) of insulin (160 IU) (f), and placebo (), respectively, on energy expenditure
were frequently measured before and after ingestion of liquid food (900 kcal; cup symbol) for a total of 6.5 h (left panel). The rise in energy
expenditure between baseline (8:30–9:45:00 A.M.) and the postprandial state (10:45:00 A.M.–3:15:00 P.M.) reﬂects the energy emitted mainly as
heat during food metabolization (diet-induced thermogenesis [DIT]) (right panel). Data are means  SEM; N  19. *P < 0.05.
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not differ between conditions during baseline (P  0.25).
Immediately after intranasal insulin administration, i.e., at
9:40 A.M., a slight and transient decrease in fasting plasma
glucose was detected (insulin vs. placebo 4.5  0.1 vs. 4.7 
0.1 mmol/l; P  0.02 [insulin/placebo main effect]), but the
subsequent postprandial increase in glucose concentrations
did not differ between conditions (AUC, 10:20 A.M.–4:00 P.M.,
insulin vs. placebo 1,574  23 vs. 1,570  20 mmol/l/min; P 
0.90) (Fig. 3A). In parallel with the slight postinsulin admin-
istration drop in plasma glucose, a small increase in serum
insulin (insulin vs. placebo 40.1  6.3 vs. 22.6  3.0 pmol/l;
P  0.01) but not in C-peptide concentrations (0.34  0.02 vs.
0.37  0.03 nmol/l; P  0.31) emerged. Following liquid food
intake, the postprandial increase in both insulin and C-
peptide concentrations was reduced by intranasal insulin in
comparison with placebo (AUC, 10:20 A.M.–4:00 P.M., serum
insulin 45,521  5,052 vs. 62,315  4,973 pmol/l/min; serum
C-peptide 409  30 vs. 487  33 nmol/l/min; P  0.001 and
P  0.02, respectively) (Fig. 3B and C). Serum FFA concen-
trations showed a transient decrease during food intake in
the insulin compared with the placebo condition (P  0.01
for condition  time) but did not differ between conditions
during the postprandial period (AUC, 10:20 A.M.–4:00 P.M.,
insulin vs. placebo 53.7  4.6 vs. 56.6  4.2 mmol/l/min; P 
0.60) (Fig. 3D).
Supplementary analyses revealed that the immediate
effects of intranasal insulin on preprandial glucose and
insulin levels as well as the prandial decrease in FFA levels
were statistically unrelated to the treatment-induced in-
crease in postprandial thermogenesis and the suppression
in postprandial serum insulin concentrations (Pearson’s
correlations; P  0.23 for all coefﬁcients).
DISCUSSION
We demonstrated in humans that acutely enhancing brain
insulin signaling by intranasal administration of the hor-
mone increases postprandial thermogenesis. The parallel
treatment-induced reduction in postprandial serum insulin
concentrations while plasma glucose levels were compa-
rable between conditions indicates that following intrana-
sal insulin administration to the brain, lower circulating
levels of the hormone are sufﬁcient to dispose of meal-
related increases in plasma glucose. In line with ﬁndings in
animals (4,5,13), our results support the notion that brain
insulin signaling in humans is involved in the control of
whole-body energy homeostasis.
In keeping with previous experiments (9,11), intranasal
administration of 160 IU insulin induced a transient and
mild increase in serum insulin concentrations accompa-
nied by a slight drop in prefood intake plasma glucose that
clearly remained within the euglycemic range. Due to the
relatively high dose administered here compared with that
in previous studies (6,8), a small ratio of the hormone may
have entered the circulation via the nasal mucosa. How-
ever, the transient nature and limited size of these imme-
diate effects argues against an involvement of systemic
uptake of intranasal insulin in its impact on postprandial
thermogenesis and glucose metabolism. This conclusion is
corroborated by the fact that immediate and postprandial
effects were not statistically related.
The balanced regulation of nutrient intake and energy
expenditure relies on the hypothalamus as a major inte-
grator of nutritional and hormonal signals from the body
periphery, including glucose and insulin (1). Direct injec-
tions of insulin into the preoptic area of the hypothalamus
induce a dose-dependent increase in core body tempera-
ture due to stimulation of brown adipose tissue thermo-
genesis that is assumed to be mediated by inhibitory
insulinergic action on warm-sensitive hypothalamic neu-
rons (3). In our experiments, intranasal administration of
the hormone to the brain did not affect resting energy
expenditure but evoked a distinct increase in postprandial
thermogenesis. Increased postprandial energy expendi-
ture due to enhanced brain insulin signaling adds to the
reduction in food intake previously observed after intra-
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FIG. 3. Intranasal insulin lowers postprandial serum insulin levels.
Concentrations of plasma glucose (A), serum insulin (B), serum C-
peptide (C), and serum free fatty acids (D) before and after acute
intranasal administration (nose symbol) of intranasal insulin (160 IU;
solid lines and black bars) and placebo (dashed lines and white bars)
followed by the standardized ingestion of 900 kcal of liquid food (cup
symbol). Postprandial levels (10:20 A.M.–4:00 P.M.) were also expressed
as AUCs (right panels). All values are presented as means  SEM. N 
19. *P < 0.05; **P < 0.01.
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the catabolic impact of central nervous insulin (10,14) is
mediated not only by anorexigenic but also by thermo-
genic effects of the hormone. Still, further studies on this
issue are needed and should include measurements of
body temperature, brown adipose tissue activity, and
relevant vital signs like heart rate and blood pressure to
elucidate the effect of brain insulin signaling on energy
expenditure in humans.
A most remarkable ﬁnding of our study is the intranasal
insulin–induced reduction in postprandial serum insulin
concentrations while the food intake-induced rise in
plasma glucose remained unaffected, suggesting that intra-
nasal insulin improves postprandial insulin sensitivity. A
regulatory effect of central nervous insulin on hepatic
glucose metabolism has been indicated by animal studies
showing that a selective decrease in hypothalamic insulin
receptors reduces hepatic insulin sensitivity and results in
marked increases in hepatic glucose production in the
presence of plasma insulin concentrations equaling those
of control animals (15). Fittingly, insulin hyperpolarizes
glucose-responsive hypothalamic neurons by opening
ATP-sensitive K
 channels (16) which triggers a decrease
in hepatic glucose production that is mediated by vagal
efferences (5,15). This pattern suggests that enhancing
brain insulin signaling by intranasal administration of the
hormone may act on glucose homeostasis in the body
periphery by supporting hepatic insulin action. Neverthe-
less, given that postprandial liver glucose production
accounts for approximately one-ﬁfth to one-half of fasting
values (17), improved insulin-dependent metabolization of
ingested glucose may also have contributed to the intra-
nasal insulin-induced decrease in postprandial serum in-
sulin levels. Such an effect could basically be supported by
the observed decrease in prandial FFA levels due to
intranasal insulin inasmuch as FFAs are known to impair
insulin-stimulated muscle uptake of glucose (18). How-
ever, FFA effects on peripheral insulin-stimulated glucose
uptake slowly develop over some hours (19), which, in
conjunction with the lack of a signiﬁcant correlation
between the decreases in prandial FFA and postprandial
insulin concentrations, makes this view unlikely. Further-
more, a contribution of enhanced noninsulin-mediated
glucose disposal, i.e., glucose effectiveness, to our effects
cannot be ruled out.
Although the present results suggest that insulin admin-
istration to the human brain enhances the efﬁciency of the
glucoregulatory brain-liver axis in response to nutrient
intake, our observations should be corroborated in future
studies that rely on more reﬁned measurements of insulin
sensitivity, e.g., euglycemic hyperinsulinemic clamps. It is
also noteworthy that most recent animal data hint at
divergent effects of hypothalamic insulinergic signaling on
peripheral glucose homeostasis and energy expenditure
depending on the involvement of agouti-related protein or
proopiomelanocortin neuronal pathways (13). In this re-
gard, general enhancements in brain insulin signaling as
performed in our study do not permit differentiations.
Taken together, our ﬁndings indicate that intranasal insu-
lin acutely increases postprandial thermogenesis and im-
proves the glucoregulatory response to food intake,
suggesting that boosting brain insulin signaling in humans
enhances the body’s ability to cope with calorie consump-
tion (20,21). Against the background of studies indicating
that obesity and peripheral insulin resistance are associ-
ated with reduced central nervous insulin sensitivity (22–
24), enhancing brain insulin signaling may emerge as a
useful approach in the therapeutic management of disor-
ders hallmarked by disturbed glucose homeostasis (25).
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